How to prevent cervical cancer: HPV – we are coming to get you!
Cervical screening and HPV testing: Opportunities for rapid tests
We explored the use of a rapid, on-demand human papillomavirus (HPV) test. Interviews with UK experts revealed that a co-located, on-demand HPV test following cytology could reduce the time to cervical screening results by up to a week, with a near-patient primary HPV test followed by cytology triage could radically change the testing paradigm. A follow-up tool we built in Excel was used to understand cervical screening burden and HPV testing across Europe.
The cost of pelvic inflammatory disease and potential cost-savings of chlamydia screening
We worked with clinicians from St Georges University who had published a trial estimating the incidence of pelvic inflammatory disease (PID) among women screened and unscreened for chlamydia. Patient data was analysed, and the average cost of managing PID was estimated to be £163 in community and hospital settings, and that over £60,000 could be saved in London alone from screening for chlamydia. This paper has been cited widely and results have informed policy and further modelling studies.
How can European countries improve cervical cancer prevention for women?
Exploring the value of a rapid, on-demand test for the detection of human papillomavirus
The benefits and cost-savings of a new point-of-care test for chlamydia and gonorrhoea
We developed an understanding of how sexual health clinics in England could use a rapid point of care test for two common sexually transmitted infections. We defined the current patient care pathways and found that the pathways could be streamlined and costs of care reduced by using point-of-care tests. The economic model developed by Aquarius Population Health showed that the test could deliver £10 million in cost savings, and give far more effective management of chlamydia and gonorrhoea at a population level.
Cost effectiveness of screening for Chlamydia trachomatis in Ireland
Costs and cost-effectiveness of different strategies for chlamydia screening and partner notification
What is the cost of pelvic inflammatory disease and how much could be prevented by screening for chlamydia?
